Literature DB >> 10529542

A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma.

M Yonekawa1, T Okabe, Y Asamoto, M Ohta.   

Abstract

We report a familial case of hereditary ceruloplasmin deficiency (HCD) showing an A-G transition in intron 6 of the ceruloplasmin gene. Clinical features consisted of chorea, cerebellar ataxia, dementia, diabetes mellitus, retinal pigmentation and iron deposition in the liver and brain without copper overload in those organs. The patient's children and siblings had similar laboratory results, but did not show any neurological abnormalities. She was medicated for diabetes mellitus at 43 years of age, and neurological signs appeared when she was 52 years old. The laboratory findings were anemia, low concentrations of iron and copper in serum and of copper in urine. Ceruloplasmin was not detected in the serum. The iron and copper contents in the liver were 3,580 and 10 microg/g wet tissue, respectively. MRI of the brain showed iron deposition in the basal ganglia, dentate nucleus and thalamus. This case did not show any abnormal increase in copper in the blood and urine following CuSO(4)5H(2)O oral overloading test. Following the intravenous administration of commercially available fresh-frozen human plasma (FFP) containing ceruloplasmin, the serum iron content increased for several hours due to ferroxidase activity of ceruloplasmin. In the liver, the iron content decreased more with the combined intravenous administration of FFP and deferoxamine than with FFP administration alone. Her neurological symptoms improved following repetitive FFP treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529542     DOI: 10.1159/000008091

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  13 in total

1.  Aceruloplasminemia: a case report.

Authors:  Domenico Di Raimondo; Antonio Pinto; Antonino Tuttolomondo; Paola Fernandez; Clara Camaschella; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-04-12       Impact factor: 3.397

Review 2.  Aceruloplasminaemia: a rare but important cause of iron overload.

Authors:  Adam Doyle; Ferry Rusli; Prithi Bhathal
Journal:  BMJ Case Rep       Date:  2015-05-14

3.  Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment.

Authors:  L Poli; A Alberici; P Buzzi; E Marchina; A Lanari; C Arosio; A Ciccone; F Semeraro; R Gasparotti; A Padovani; Barbara Borroni
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

Review 4.  Decreased T2 signal in the thalami may be a sign of lysosomal storage disease.

Authors:  Taina Autti; Raimo Joensuu; Laura Aberg
Journal:  Neuroradiology       Date:  2007-03-03       Impact factor: 2.804

5.  Clinical and imaging characteristics of late onset mitochondrial membrane protein-associated neurodegeneration (MPAN).

Authors:  Ethan Gore; Brian S Appleby; Mark L Cohen; Suzanne D DeBrosse; James B Leverenz; Bruce L Miller; Sandra L Siedlak; Xiongwei Zhu; Alan J Lerner
Journal:  Neurocase       Date:  2016-11-01       Impact factor: 0.881

6.  Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Authors:  R Mariani; C Arosio; S Pelucchi; M Grisoli; A Piga; P Trombini; A Piperno
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

8.  Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Authors:  Armin Finkenstedt; Elisabeth Wolf; Elmar Höfner; Bethina Isasi Gasser; Sylvia Bösch; Rania Bakry; Marc Creus; Christian Kremser; Michael Schocke; Milan Theurl; Patrizia Moser; Melanie Schranz; Guenther Bonn; Werner Poewe; Wolfgang Vogel; Andreas R Janecke; Heinz Zoller
Journal:  J Hepatol       Date:  2010-08-04       Impact factor: 25.083

9.  Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia.

Authors:  Alan Zanardi; Antonio Conti; Marco Cremonesi; Patrizia D'Adamo; Enrica Gilberti; Pietro Apostoli; Carlo Vittorio Cannistraci; Alberto Piperno; Samuel David; Massimo Alessio
Journal:  EMBO Mol Med       Date:  2018-01       Impact factor: 12.137

10.  Genetic and Clinical Heterogeneity in Thirteen New Cases with Aceruloplasminemia. Atypical Anemia as a Clue for an Early Diagnosis.

Authors:  Marc Vila Cuenca; Giacomo Marchi; Anna Barqué; Clara Esteban-Jurado; Alessandro Marchetto; Alejandro Giorgetti; Viorica Chelban; Henry Houlden; Nicholas W Wood; Chiara Piubelli; Marina Dorigatti Borges; Dulcinéia Martins de Albuquerque; Kleber Yotsumoto Fertrin; Ester Jové-Buxeda; Jordi Sanchez-Delgado; Neus Baena-Díez; Birute Burnyte; Algirdas Utkus; Fabiana Busti; Gintaras Kaubrys; Eda Suku; Kamil Kowalczyk; Bartosz Karaszewski; John B Porter; Sally Pollard; Perla Eleftheriou; Patricia Bignell; Domenico Girelli; Mayka Sanchez
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.